Show simple item record

dc.contributor.authorCorvillo, Fernando
dc.contributor.authorCeccarini, Giovanni
dc.contributor.authorNozal, Pilar
dc.contributor.authorMagno, Silvia
dc.contributor.authorPelosini, Caterina
dc.contributor.authorGarrido, Sofía
dc.contributor.authorLópez-Lera, Alberto
dc.contributor.authorMoraru, Manuela
dc.contributor.authorVilches Ruiz, Blas Carlos 
dc.contributor.authorFornaciari, Silvia
dc.contributor.authorGabbriellini, Sabrina
dc.contributor.authorSantini, Ferruccio
dc.contributor.authorAraújo-Vilar, David
dc.contributor.authorLópez Trascasa, Margarita 
dc.contributor.otherUAM. Departamento de Medicinaes_ES
dc.contributor.otherInstituto de Investigación Sanitaria Hospital Universitario de La Paz (IdiPAZ)es_ES
dc.date.accessioned2020-12-02T09:02:35Z
dc.date.available2020-12-02T09:02:35Z
dc.date.issued2020-01-10
dc.identifier.citationOrphanet Journal of Rare Diseases 15 (2020): 9en_US
dc.identifier.issn1750-1172es_ES
dc.identifier.urihttp://hdl.handle.net/10486/692629
dc.description.abstractBackground: C3 hypocomplementemia and the presence of C3 nephritic factor (C3NeF), an autoantibody causing complement system over-activation, are common features among most patients affected by Barraquer-Simons syndrome (BSS), an acquired form of partial lipodystrophy. Moreover, BSS is frequently associated with autoimmune diseases. However, the relationship between complement system dysregulation and BSS remains to be fully elucidated. The aim of this study was to provide a comprehensive immunological analysis of the complement system status, autoantibody signatures and HLA profile in BSS. Thirteen subjects with BSS were recruited for the study. The circulating levels of complement components, C3, C4, Factor B (FB) and Properdin (P), as well as an extended autoantibody profile including autoantibodies targeting complement components and regulators were assessed in serum. Additionally, HLA genotyping was carried out using DNA extracted from peripheral blood mononuclear cells. Results: C3, C4 and FB levels were significantly reduced in patients with BSS as compared with healthy subjects. C3NeF was the most frequently found autoantibody (69.2% of cases), followed by anti-C3 (38.5%), and anti-P and anti- FB (30.8% each). Clinical data showed high prevalence of autoimmune diseases (38.5%), the majority of patients (61.5%) being positive for at least one of the autoantibodies tested. The HLA allele DRB1*11 was present in 54% of BSS patients, and the majority of them (31%) were positive for *11:03 (vs 1.3% allelic frequency in the general population). Conclusions: Our results confirmed the association between BSS, autoimmunity and C3 hypocomplementemia. Moreover, the finding of autoantibodies targeting complement system proteins points to complement dysregulation as a central pathological event in the development of BSS.en_US
dc.description.sponsorshipThis work was supported by Instituto de Salud Carlos III (Ministerio de Ciencia, Innovación y Universidades, Gobierno de España) and Fondos FEDER (PI15–00255 to M.L-T. and PI08–1449 to D.A-V.), Complemento II-CM network (B2017/BMD3673 to M.L-T), the intramural research program of the Xunta de Galicia (Programa de Consolidación e Estructuración de Unidades de Investigación Competitivas, grant ED341b 2017/19 to D.A-V.), the Asociación Española de Familiares y Afectados de Lipodistrofias (AELIP) (to D.A-V., to F.C. and to P.N.)en_US
dc.format.extent11 pag.es_ES
dc.format.mimetypeapplication/pdfen
dc.language.isoengen_US
dc.publisherBMC part of Springer Natureen_US
dc.relation.ispartofOrphanet Journal of Rare Diseasesen_US
dc.rights© 2020 The Authorsen_US
dc.subject.otherComplement systemen_US
dc.subject.otherLipodystrophyen_US
dc.subject.otherBarraquer-Simons syndromeen_US
dc.subject.otherC3 nephritic factoren_US
dc.subject.otherAutoimmunityen_US
dc.subject.otherAcquired partial lipodystrophyen_US
dc.titleImmunological features of patients affected by Barraquer-Simons syndromeen_US
dc.typearticleen
dc.subject.ecienciaMedicinaes_ES
dc.relation.publisherversionhttp://doi.org/10.1186/s13023-019-1292-1es_ES
dc.identifier.doi10.1186/s13023-019-1292-1es_ES
dc.identifier.publicationfirstpage9-1es_ES
dc.identifier.publicationlastpage9-11es_ES
dc.identifier.publicationvolume15es_ES
dc.relation.projectIDGobierno de España. PI15–00255es_ES
dc.relation.projectIDGobierno de España. B2017/BMD3673es_ES
dc.type.versioninfo:eu-repo/semantics/publishedVersionen
dc.rights.ccReconocimientoes_ES
dc.rights.accessRightsopenAccessen
dc.authorUAMVilches Ruiz, Blas Carlos (260426)
dc.authorUAMLópez Trascasa, Margarita (262123)
dc.facultadUAMFacultad de Medicina
dc.institutoUAMInstituto de Investigación Sanitaria Hospital Universitario de La Paz (IdiPAZ)


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record